retatrutide triple agonist obesity phase 2 trial glp-1 gip glucagon results Retatrutide, a GIP, and receptor agonist Retatrutide for Obesity: Phase 2

Yilmaz, L

Enrollment increased by 1,057% to 347 in 2024 and reached 186 in the first 5 months of 2025

However, if this mechanism persists, it may lead to different metabolic diseases 56 and NDs

Addingly, another study not only showed increased iron concentration in SN pars compacta of early-stage PD patients compared to controls, but in those with late-stage PD apart from affecting SN pars compacta, other areas such as red nucleus and globus pallidus became involved suggesting a regionally progressive accumulation that is consistent with the stage of the disease ( in vivo assessment of iron dysregulation and supports the thesis that region-specific brain iron accumulation could represent a valuable biomarker in diagnosis, prognosis and disease monitoring in PD and parkinsonism ( Potential association between iron metabolism and T2DM pathobiology has been studied in vivo on a Chinese population of T2DM of middle-aged and elderly patients with evidence of a linear correlation between ferritin levels and risk of developing T2DM (Sun et al., 2013)

This selective targeting underpins their efficacy in enhancing insulin secretion, inhibiting glucagon release, and promoting metabolic control in diabetes management (29)

Ty theo tnh trng sc khe c th, bc s c th k liu cao hn